Loading...
Market
Will Pfizer face lawsuits due to Oxbryta withdrawal by December 31, 2024?
3
Resolution / Starting Odds
Yes • 50%
No • 50%
Publicly available legal documents, news reports, or official Pfizer statements
Story
Pfizer Withdraws Sickle Cell Treatment Oxbryta from Global Markets Due to Safety Concerns, $5.4 Billion Acquisition Impacted
Sep 25, 2024, 09:30 PM
Pfizer Inc. announced it is voluntarily withdrawing all lots of its sickle cell disease treatment, Oxbryta (voxelotor), from worldwide markets due to safety concerns. The decision follows data indicating an imbalance in vaso-occlusive crises and fatal events associated with the drug. Oxbryta was acquired by Pfizer in a $5.4 billion deal with Global Blood Therapeutics in 2022.
View original story
Similar markets
Yes • 50%
No • 50%
No action taken • 25%
Warning issued • 25%
Fine imposed • 25%
Other sanctions • 25%
Increase by more than 10% • 25%
Increase by less than 10% • 25%
Decrease by less than 10% • 25%
Decrease by more than 10% • 25%
Yes • 50%
No • 50%
Yes • 50%
No • 50%
Yes • 50%
No • 50%
Yes • 50%
No • 50%
Yes • 50%
No • 50%
Verdict upheld • 25%
Verdict overturned • 25%
Settlement reached • 25%
Other • 25%
Counter-sue • 33%
Motion to dismiss • 33%
Settlement offer • 33%